HORIZON SCAN
Chelonia's research focus areas
Chelonia's strategic themes for future research
Real-world data (RWD) is continuously generated through interactions with the healthcare system-ranging from doctor visits and pharmacy records to data collected by wearable devices. Despite its fragmented and heterogeneous nature, there is an ongoing global effort to integrate RWD in ways that enhance healthcare delivery, improve clinical decisions, and support health innovation.
Chelonia is actively developing advanced AI/ML algorithms designed to fuse multilayered data-combining physiological, behavioral, contextual, and environmental signals-to deliver meaningful insights across diverse domains.
A key application of RWD is the generation of real-world evidence (RWE) for observational studies, providing complementary insights to those obtained from randomized clinical trials. This integrated approach enables a more holistic understanding of treatment effectiveness, safety, and patient outcomes.
Beyond healthcare, Chelonia’s data fusion and predictive modeling technologies are being tested in high-impact areas such as:
NATURAL EVENTS AND PANDEMIC PREPAREDNESS
FINANCIAL MARKETS
CLINICAL TRIALS
Bacteriophages-viruses that selectively infect bacteria-are emerging as highly adaptable biological tools to modulate the human microbiome, a complex ecosystem of microorganisms essential to human health. Through synthetic biology and molecular reprogramming, phages can now be engineered to precisely target individual bacterial species, eliminate pathogenic strains, or activate therapeutic functions within commensal bacteria.
These “designer phages” hold the potential to treat microbiome-associated diseases, restore antibiotic sensitivity in resistant bacteria, and deliver functional genetic elements directly into microbial ecosystems. Beyond healthcare, similar strategies are being explored to enhance agricultural productivity and promote animal health, using microbiome modulation as a sustainable alternative to chemical treatments.
Encouraged by promising preclinical results, the field is attracting growing interest from both academic institutions and private investors, with early clinical trials already underway.
Chelonia is currently leading the design of a new international research effort to advance the development of engineered phages for clinical and translational applications. The initiative brings together leading clinical and microbiome research centers from Europe, the United States, and South Korea, combining expertise in synthetic biology, infectious diseases, regulatory science, and AI-driven therapeutic design.
By connecting molecular innovation with real-world clinical needs, Chelonia aims to accelerate the transition of designer phages from experimental tools to scalable, precision interventions in human, animal, and environmental health.
Pharmaceutical pipelines are filled with discontinued compounds—assets once backed by promising science but shelved due to strategic shifts, incomplete data, or misaligned incentives. Yet many of these molecules retain known safety profiles, established manufacturing routes, and untapped therapeutic potential.
Recognizing this opportunity, Chelonia designed and structured a dedicated initiative to unlock the latent value of these dormant assets. Working closely with some of the world’s largest pharmaceutical groups active in drug discovery and repurposing, Chelonia has built a high-level operational team and an elite Scientific Advisory Board, featuring Nobel Laureates and C-level pharma executives.
This effort is now evolving into an independent spin-off, founded on Chelonia’s original strategic blueprint and scientific vision. The project combines advanced data analytics, translational expertise, and industry insight to bring discontinued compounds back into the therapeutic arena—faster, smarter, and with reduced risk.
By transforming loss into opportunity, Chelonia has once again demonstrated its ability to architect innovation where others see dead ends.
